Lv3
218 积分 2025-01-07 加入
Rare immune adverse event in treatment of non-small-cell lung carcinoma: durvalumab-associated optic neuritis
13天前
已完结
Durvalumab-associated membranous nephropathy: a case report and brief literature review
13天前
已完结
Characterizing pulmonary adverse events associated with the immune checkpoint inhibitor avelumab: a FAERS-based pharmacovigilance study from 2013 to 2024
13天前
已完结
Sjogren's syndrome due to immune checkpoint inhibitors (ICIs): Insights from a single-institution series and systematic review of the literature
13天前
已完结
A case of zolbetuximab-induced protein-losing gastroenteropathy in a patient with advanced gastric cancer
13天前
已完结
Two cases of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancer
13天前
已完结
11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050
1个月前
已完结
Efficacy and safety of fibroblast growth factor 21 analogs in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis: A systematic review and network meta-analysis
2个月前
已完结
Efficacy and safety of fibroblast growth factor 21 analogs in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis: A systematic review and network meta-analysis
2个月前
已关闭
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
2个月前
已完结
皖公网安备34019202002308
